NYSE:LLY News 30 November 2025

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

HUNTSVILLE, Ala. — December 9, 2025 Eli Lilly and Company will invest more than $6 billion in a new advanced pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 high‑value permanent jobs and an estimated 3,000 construction jobs in what state

10 December 2025

Eli Lilly Stock After Hours on December 9, 2025: 9‑Day Slide, $6B Alabama Bet and What to Watch Before the December 10 Open

Eli Lilly and Company (NYSE: LLY) closed lower again on Tuesday, December 9, extending a rare nine‑session losing streak even as the drugmaker announced a multibillion‑dollar U.S. manufacturing expansion and positive cancer‑drug trial data. StockAnalysis+1 Heading into the U.S. stock

10 December 2025

Earnings Reports · Financial News · Investing · NYSE:LLY · Pharma Industry · Stock Market

Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

As of Tuesday, December 9, 2025, Eli Lilly (NYSE: LLY) sits at the center of nearly every conversation about obesity drugs, oncology breakthroughs and “next trillion‑dollar” stocks. The shares trade around $980 per share, down about 1.6% on the day but

9 December 2025

Company News · Investment Insights · Market Forecasts · NYSE:LLY · Pharmaceutical Industry · Stock Analysis

Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly and Company (NYSE: LLY) is once again in the spotlight. As of early trading on December 9, 2025, Eli Lilly stock is hovering around $997 per share, roughly 10% below its late‑November all‑time high but still up about

9 December 2025

Drug Developments · Investment Insights · Market Outlook · NYSE:LLY · Pharma News · Stock Analysis

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly and Company (NYSE: LLY) spent Monday, December 8, 2025, digesting a wave of news: a major reimbursement win for Mounjaro in China, a 15% dividend hike, new leukemia drug data, and the return of Nobel laureate Carolyn Bertozzi

9 December 2025

Dividends · Earnings Reports · Investing · NYSE:LLY · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Stock on December 8, 2025: China Insurance Win, Trillion‑Dollar Status and What Comes Next for Investors

Updated: December 8, 2025 – For informational purposes only, not investment advice. Key takeaways 1. Where Eli Lilly (LLY) stands on December 8, 2025 As U.S. markets trade on Monday, Eli Lilly and Company (NYSE: LLY) is changing hands near

8 December 2025

Financial News · Investing · Market Analysis · NYSE:LLY · Pharma Industry · Stock Market

Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

As Wall Street heads into Monday’s session, Eli Lilly and Company (NYSE: LLY) sits at the center of several big storylines: Chinese market access for its Alzheimer’s drug, a fresh FDA decision and new data for cancer therapy Jaypirca, price

7 December 2025

Financial News · Investing · Market Analysis · NYSE:LLY · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly and Company (NYSE: LLY) heads into the final weeks of 2025 as one of the most closely watched stocks on Wall Street – and not just in healthcare. After briefly crossing the $1 trillion market-cap mark in November

6 December 2025

Company News · Financial Forecasts · Investment Analysis · NYSE:LLY · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Stock Today, 4 December 2025: Zepbound Price Cuts, Jaypirca FDA Win and New $1,200–$1,500 Targets

Date: 4 December 2025 Eli Lilly stock at a glance Eli Lilly and Company (NYSE: LLY) is trading around $1,030–$1,040 per share on 4 December 2025, down roughly 1% on the session after slipping from about $1,046 in the previous

4 December 2025

FDA Approvals · Investment Analysis · NYSE:LLY · Pharmaceuticals · Price Targets · Stock Market

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025. Eli Lilly Stock

2 December 2025

Business News · Healthcare · Investing · NYSE:LLY · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

As of December 1, 2025, Eli Lilly and Company (NYSE: LLY) is trading around $1,075 per share, giving the drugmaker a market capitalization of roughly $1.0–1.02 trillion and cementing its status as the first pharmaceutical company to enter the trillion‑dollar

1 December 2025

Company Analysis · Financial Forecasts · Investment · NYSE:LLY · Pharma News · Stock Market

Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Published: November 30, 2025 Eli Lilly and Company (NYSE: LLY) heads into Monday’s session after one of the most consequential months in its history: a brief stint above a $1 trillion market value, a huge November rally powered by obesity

30 November 2025

Financial News · Investing · Market Analysis · NYSE:LLY · Pharmaceuticals · Stock Market

NYSE:LLY News 30 November 2025 - 10 December 2025